NICE has issued final guidance on the use rituximab for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated people (TA 243).

The guidance recommends rituximab in combination with the following as a treatment option:

• cyclophosphamide, vincristine and prednisolone (CVP)

• cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) mitoxantrone, chlorambucil and prednisolone (MCP)

• cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-α (CHVPi)

• chlorambucil